Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;51(5):e12475.
doi: 10.1111/cpr.12475. Epub 2018 Jul 30.

Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37

P Conti  1 , Al Caraffa  2 , F Mastrangelo  3 , L Tettamanti  4 , G Ronconi  5 , I Frydas  6 , S K Kritas  7 , T C Theoharides  8
Affiliations
Review

Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37

P Conti et al. Cell Prolif. 2018 Oct.

Abstract

Background: Fibrosis involves the activation of inflammatory cells, leading to a decrease in physiological function of the affected organ or tissue.

Aims: To update and synthesize relevant information concerning fibrosis into a new hypothesis to explain the pathogenesis of fibrosis and propose potential novel therapeutic approaches.

Materials and methods: Literature was reviewed and relevant information is discussed in the context of the pathogenesis of fibrosis.

Results: A number of cytokines and their mRNA are involved in the circulatory system and in organs of patients with fibrotic tissues. The profibrotic cytokines are generated by several activated immune cells, including fibroblasts and mast cells (MCs), which are important for tissue inflammatory responses to different types of injury. MC-derived TNF, IL-1, and IL-33 contribute crucially to the initiation of a cascade of the host defence mechanism(s), leading to the fibrosis process. Inhibition of TNF and inflammatory cytokines may slow the progression of fibrosis and improve the pathological status of the affected subject. IL-37 is generated by various types of immune cells and is an IL-1 family member protein. IL-37 is not a receptor antagonist; it binds IL-18 receptor alpha (IL-18Rα) and delivers the inhibitory signal by using TIR8. It has been shown that IL-37 can be protective in inflammation and injury, and inhibits both innate and adaptive immunity.

Discussion: IL-37 may be useful for suppression of inflammatory diseases induced by inhibiting MyD88-dependent TLR signalling. In addition, IL-37 downregulates NF-κB induced by TLR2 or TLR4 through a mechanism dependent on IL-18Rα.

Conclusion: This review summarizes current knowledge on the role of MC in inflammation and tissue/organ fibrosis, with a focus on the therapeutic potential of IL-37-targeting cytokines.

Keywords: IL-37; cytokine; fibrosis; immunity; mast cells.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest relevant to this article. The authors alone are responsible for the content and writing of the article.

Figures

Figure 1
Figure 1
Mast cell‐mediated tissue fibrosis. This figure depicts a tissue which releases TGF‐β, activating monocyte which participate in angiogenesis and fibrosis. In addition, activated mast cells release chemical mediators, TGF‐β and angiotensin II, which also participate in fibrotic processes
Figure 2
Figure 2
Production of anti‐inflammatory and proinflammatory cytokines. Macrophage activation releases IL‐37 which inhibits MyD88. Dendritic cells activated after maturation release proinflammatory and anti‐inflammatory cytokines. Proinflammatory IL‐1 family members are inhibited by IL‐37 generated by activated macrophage
See this image and copyright information in PMC

References

    1. Dinarello CA, Conti P, Mier JW. Effects of human interleukin‐1 on natural killer cell activity: is fever a host defense mechanism for tumor killing? Yale J Biol Med. 1986;59:97‐106. - PMC - PubMed
    1. Robuffo I, Toniato E, Tettamanti L, et al. Mast cell in innate immunity mediated by proinflammatory and antiinflammatory IL‐1 family members. J Biol Regul Homeost Agents. 2017;31:837‐842. - PubMed
    1. Iannitti RG, Napolioni V, Oikonomou V, et al. IL‐1 receptor antagonist ameliorates inflammasome‐dependent inflammation in murine and human cystic fibrosis. Nat Commun. 2016;7:10791. - PMC - PubMed
    1. Artlett CM. The IL‐1 family of cytokines. Do they have a role in scleroderma fibrosis? Immunol Lett. 2017;195:30‐37. 10.1016/j.imlet.2017.11.012. - DOI - PubMed
    1. Mack M. Inflammation and fibrosis. Matrix Biol. 2017; Nov 28. pii: S0945‐053X(17)30375‐X. doi: 10.1016/j.matbio.2017.11.010. [Epub ahead of print] Review. 10.1016/j.matbio.2017.11.010. - DOI - DOI